{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:00:09Z","timestamp":1790838009876,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin. Auton. Res."],"DOI":"10.1007\/s10286-026-01247-8","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:36:03Z","timestamp":1790836563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Two dopaminergic systems, one bladder: recognising a therapy-resistant urinary phenotype in Parkinson\u2019s disease"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-3760","authenticated-orcid":false,"given":"Mario","family":"Hero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimira","family":"Vuleti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"5","key":"1247_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/mdc3.12374","volume":"3","author":"A Batla","year":"2016","unstructured":"Batla A, Ph\u00e9 V, De Min L, Panicker JN (2016) Nocturia in Parkinson\u2019s disease: why does it occur and how to manage? Mov Disord Clin Pract 3(5):443\u2013451","journal-title":"Mov Disord Clin Pract"},{"key":"1247_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.parkreldis.2016.10.024","volume":"35","author":"C McDonald","year":"2017","unstructured":"McDonald C, Winge K, Burn DJ (2017) Lower urinary tract symptoms in Parkinson\u2019s disease: prevalence, aetiology and management. Parkinsonism Relat Disord 35:8\u201316","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"1247_CR3","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/iju.12421","volume":"21","author":"R Sakakibara","year":"2014","unstructured":"Sakakibara R, Tateno F, Nagao T et al (2014) Bladder function of patients with Parkinson\u2019s disease. Int J Urol 21(7):638\u2013646","journal-title":"Int J Urol"},{"issue":"2\u20133","key":"1247_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.baga.2015.06.001","volume":"5","author":"SL Alberico","year":"2015","unstructured":"Alberico SL, Cassell MD, Narayanan NS (2015) The vulnerable ventral tegmental area in Parkinson\u2019s disease. Basal Ganglia 5(2\u20133):51\u201355","journal-title":"Basal Ganglia"},{"issue":"2","key":"1247_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0304-3940(85)90132-6","volume":"56","author":"B Conte-Devolx","year":"1985","unstructured":"Conte-Devolx B, Grino M, Nieoullon A et al (1985) Corticoliberin, somatocrinin and amine contents in normal and parkinsonian human hypothalamus. Neurosci Lett 56(2):217\u2013222","journal-title":"Neurosci Lett"},{"issue":"18","key":"1247_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1212\/01.wnl.0000260605.12506.86","volume":"68","author":"L Brusa","year":"2007","unstructured":"Brusa L, Petta F, Pisani A et al (2007) Acute vs chronic effects of L-dopa on bladder function in patients with mild Parkinson disease. Neurology 68(18):1455\u20131459","journal-title":"Neurology"},{"key":"1247_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116625","volume":"410","author":"L Brusa","year":"2019","unstructured":"Brusa L, Ponzo V, Stefani A et al (2019) Extended release levodopa at bedtime as a treatment for nocturia in Parkinson\u2019s disease: an open label study. J Neurol Sci 410:116625","journal-title":"J Neurol Sci"},{"key":"1247_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105394","volume":"112","author":"D Rinaldi","year":"2023","unstructured":"Rinaldi D, Galli S, Fanciulli A, Pontieri FE (2023) Levodopa\/carbidopa intestinal gel via percutaneous endoscopic transgastric jejunostomy in advanced Parkinson\u2019s disease: hitting two birds with one stone? Parkinsonism Relat Disord 112:105394","journal-title":"Parkinsonism Relat Disord"},{"key":"1247_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.parkreldis.2020.08.032","volume":"79","author":"E J\u00f6rg","year":"2020","unstructured":"J\u00f6rg E, Sartori AM, Hofer AS, Baumann CR, Kessler TM (2020) Deep brain stimulation effects on lower urinary tract function: systematic review and meta-analysis. Parkinsonism Relat Disord 79:65\u201372","journal-title":"Parkinsonism Relat Disord"},{"issue":"Pt 1","key":"1247_CR10","first-page":"132","volume":"131","author":"J Herzog","year":"2008","unstructured":"Herzog J, Weiss PH, Assmus A et al (2008) Improved sensory gating of urinary bladder afferents in Parkinson\u2019s disease following subthalamic stimulation. Brain 131(Pt 1):132\u2013145","journal-title":"Brain"},{"issue":"6","key":"1247_CR11","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.euf.2022.05.004","volume":"8","author":"AM Sartori","year":"2022","unstructured":"Sartori AM, Kiss B, Mordasini L et al (2022) Effects of deep brain stimulation on lower urinary tract function in neurological patients. Eur Urol Focus 8(6):1775\u20131782","journal-title":"Eur Urol Focus"},{"issue":"1","key":"1247_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.expneurol.2008.07.021","volume":"214","author":"M Politis","year":"2008","unstructured":"Politis M, Piccini P, Pavese N, Koh SB, Brooks DJ (2008) Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson\u2019s disease: an in vivo 11C-raclopride PET study. Exp Neurol 214(1):112\u2013116","journal-title":"Exp Neurol"},{"issue":"1","key":"1247_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1212\/CON.0000000000000824","volume":"26","author":"JN Panicker","year":"2020","unstructured":"Panicker JN, Sakakibara R (2020) Lower urinary tract and bowel dysfunction in neurologic disease. Continuum (Minneap Minn) 26(1):178\u2013199","journal-title":"Continuum (Minneap Minn)"},{"key":"1247_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105822","volume":"115","author":"DS Abraham","year":"2023","unstructured":"Abraham DS, Pham Nguyen TP, Newcomb CW et al (2023) Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease. Parkinsonism Relat Disord 115:105822","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Clinical Autonomic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-026-01247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10286-026-01247-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-026-01247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:36:03Z","timestamp":1790836563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10286-026-01247-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":14,"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1007\/s10286-026-01247-8","relation":{},"ISSN":["0959-9851","1619-1560"],"issn-type":[{"value":"0959-9851","type":"print"},{"value":"1619-1560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mario Hero: conceptualization, writing\u2014original draft and writing\u2014review and editing. Vladimira Vuleti\u0107: writing\u2014review and editing and supervision.","order":2,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No new data were generated or analysed in support of this correspondence.","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}